Insider Buying: Vigil Neuroscience, Inc. (NASDAQ:VIGL) General Counsel Acquires 4,000 Shares of Stock

Vigil Neuroscience, Inc. (NASDAQ:VIGLGet Rating) General Counsel Christopher Verni acquired 4,000 shares of the firm’s stock in a transaction on Tuesday, May 3rd. The shares were acquired at an average price of $3.77 per share, with a total value of $15,080.00. Following the completion of the purchase, the general counsel now owns 4,000 shares in the company, valued at approximately $15,080. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of NASDAQ VIGL opened at $3.61 on Wednesday. The business has a fifty day moving average of $9.14. Vigil Neuroscience, Inc. has a one year low of $3.06 and a one year high of $18.27.

Several equities analysts recently issued reports on VIGL shares. Jefferies Financial Group started coverage on shares of Vigil Neuroscience in a research note on Tuesday, February 1st. They issued a “buy” rating and a $20.00 target price for the company. Morgan Stanley started coverage on shares of Vigil Neuroscience in a research note on Tuesday, February 1st. They issued an “equal weight” rating and a $17.00 target price for the company. Stifel Nicolaus started coverage on shares of Vigil Neuroscience in a research note on Tuesday, February 1st. They issued a “buy” rating and a $24.00 target price for the company. Finally, Guggenheim started coverage on shares of Vigil Neuroscience in a research note on Tuesday, February 1st. They issued a “buy” rating and a $23.00 target price for the company.

Vigil Neuroscience Company Profile (Get Rating)

Vigil Neuroscience, Inc, a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease.

Featured Stories

Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.